<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="leopard" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">leopard</book-part-id>
      <title-group>
        <title>Noonan Syndrome with Multiple Lentigines</title>
        <alt-title alt-title-type="alt-title">Synonyms: LEOPARD Syndrome, Multiple Lentigines Syndrome</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gelb</surname>
            <given-names>Bruce D</given-names>
          </name>
          <degrees>MD</degrees>
          <email>bruce.gelb@mssm.edu</email>
          <aff>Departments of Pediatrics and Genetics and Genomic Sciences<break/>Mindich Child Health and Development Institute<break/>Icahn School of Medicine at Mount Sinai<break/>New York, NY</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tartaglia</surname>
            <given-names>Marco</given-names>
          </name>
          <degrees>PhD</degrees>
          <email>marco.tartaglia@iss.it</email>
          <aff>Dipartimento di Ematologia, Oncologia e Medicina Molecolare<break/>Istituto Superiore di Sanit&#x000e0;<break/>Rome, Italy</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2007-11-30" date-type="created">
          <day>30</day>
          <month>11</month>
          <year>2007</year>
        </date>
        <date iso-8601-date="2015-05-14" date-type="updated">
          <day>14</day>
          <month>5</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="noonan" document-type="chapter">Noonan Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="leigh-nucl-ov" document-type="chapter">Nuclear Gene-Encoded Leigh Syndrome Overview</related-object>
      <abstract id="leopard.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Noonan syndrome with multiple lentigines (NSML) is a condition in which the cardinal features consist of lentigines, hypertrophic cardiomyopathy, short stature, pectus deformity, and dysmorphic facial features, including widely spaced eyes and ptosis. Multiple lentigines present as dispersed flat, black-brown macules, mostly on the face, neck and upper part of the trunk with sparing of the mucosa. In general, lentigines do not appear until age four to five years but then increase to the thousands by puberty. Some individuals with NSML do not exhibit lentigines. Approximately 85% of affected individuals have heart defects, including hypertrophic cardiomyopathy (HCM) (typically appearing during infancy and sometimes progressive) and pulmonary valve stenosis. Postnatal growth retardation resulting in short stature occurs in fewer than 50% of affected persons, although most affected individuals have a height that is less than the 25<sup>th</sup> percentile for age. Sensorineural hearing deficits, present in approximately 20%, are poorly characterized. Intellectual disability, typically mild, is observed in approximately 30% of persons with NSML.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of NSML is established either by clinical findings or, if clinical findings are insufficient, by identification of a heterozygous pathogenic variant in one of four genes (<italic toggle="yes">PTPN11</italic>, <italic toggle="yes">RAF1</italic>, <italic toggle="yes">BRAF</italic>, and <italic toggle="yes">MAP2K1</italic>) by molecular genetic testing. At least one additional gene in which mutation is causative is likely to exist.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: Treatment of cardiovascular anomalies and cryptorchidism is the same as in the general population. Treatment of hearing loss includes hearing aids, enrollment in an educational program for the hearing impaired, and consideration of cochlear implantation. Developmental disability is managed by early intervention programs and individualized education strategies.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> For individuals with hypertrophic cardiomyopathy, certain physical activities may be curtailed in order to reduce the risk of sudden cardiac death.</p>
          <p><italic toggle="yes">Surveillance</italic>: Periodic follow up and often lifelong monitoring may be necessary for any abnormality, especially a cardiovascular abnormality. For hearing loss, twice-yearly examination by a physician familiar with hereditary hearing impairment and repeat audiometry to confirm the stability of the hearing loss are recommended. Routine monitoring of developmental progress and linear growth in childhood and adolescence.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> For individuals with hypertrophic cardiomyopathy, treatment with growth hormone must be undertaken with great caution, if at all, to avoid exacerbating a cardiac condition.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> Affected women with hypertrophic cardiomyopathy or valve dysfunction may be at risk for development or exacerbation of heart failure during pregnancy; cardiac status in these women should be monitored, especially during the 2<sup>nd</sup> and 3<sup>rd</sup> trimesters of pregnancy.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>NSML is inherited in an autosomal dominant manner. A proband with NSML may have the disorder as the result of new gene mutation; the proportion of cases caused by <italic toggle="yes">de novo</italic> mutation is unknown. Each child of an individual with NSML has a 50% chance of inheriting the pathogenic variant. Prenatal diagnosis for pregnancies at increased risk is possible if the pathogenic variant in an affected family member is known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="leopard.Diagnosis">
        <title>Diagnosis</title>
        <sec id="leopard.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Noonan syndrome with multiple lentigines (NSML) <bold>should be suspected</bold> in individuals with one or more of the following cardinal features:</p>
          <list list-type="bullet">
            <list-item>
              <p>Lentigines</p>
            </list-item>
            <list-item>
              <p>Cardiac abnormalities, particularly hypertrophic cardiomyopathy</p>
            </list-item>
            <list-item>
              <p>Poor linear growth/short stature</p>
            </list-item>
            <list-item>
              <p>Pectus deformity</p>
            </list-item>
            <list-item>
              <p>Dysmorphic facial features, including widely spaced eyes and ptosis</p>
            </list-item>
          </list>
          <p>Additional features occurring frequently in NSML:</p>
          <list list-type="bullet">
            <list-item>
              <p>Variable degree of cognitive deficits</p>
            </list-item>
            <list-item>
              <p>Sensorineural hearing loss</p>
            </list-item>
            <list-item>
              <p>Cryptorchidism</p>
            </list-item>
            <list-item>
              <p>Skeletal anomalies</p>
            </list-item>
            <list-item>
              <p>Caf&#x000e9;-au-lait macules</p>
            </list-item>
          </list>
        </sec>
        <sec id="leopard.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of Noonan syndrome with multiple lentigines is established either clinically in a proband with the following clinical findings or, if clinical findings are insufficient, by identification of a heterozygous pathogenic variant in one of four genes (<italic toggle="yes">PTPN11</italic>, <italic toggle="yes">RAF1</italic>, <italic toggle="yes">BRAF</italic>, and <italic toggle="yes">MAP2K1)</italic> by molecular genetic testing (see <xref ref-type="table" rid="leopard.T.summary_of_molecular_genetic_t">Table 1</xref>).</p>
          <p>
            <bold>Clinical findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Multiple lentigines plus two of the other cardinal features OR</p>
            </list-item>
            <list-item>
              <p>In the absence of lentigines, three of the other cardinal features plus a first-degree relative with NSML [<xref ref-type="bibr" rid="leopard.REF.sarkozy.2008.13">Sarkozy et al 2008</xref>]</p>
            </list-item>
          </list>
          <p><bold>Molecular genetic testing</bold> approaches can include <bold>single-gene testing</bold> and use of a <bold>multi-gene panel.</bold></p>
          <list list-type="bullet">
            <list-item>
              <p>A multi-gene panel that includes <italic toggle="yes">PTPN11</italic>, <italic toggle="yes">RAF1</italic>, <italic toggle="yes">BRAF</italic>, <italic toggle="yes">MAP2K1</italic>, and other genes of interest (see <xref ref-type="sec" rid="leopard.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and sensitivity of multi-gene panels vary by laboratory and over time.</p>
            </list-item>
            <list-item>
              <p><bold>Serial single-gene testing</bold> of <italic toggle="yes">PTPN11</italic>, <italic toggle="yes">RAF1,</italic>
<italic toggle="yes">BRAF</italic>, and <italic toggle="yes">MAP2K1</italic> based on the order in which a pathogenic variant is most likely to be identified. Although gene-targeted deletion/duplication analysis could be considered, the mutation detection frequency is unknown and expected to be extremely low.</p>
            </list-item>
          </list>
          <table-wrap id="leopard.T.summary_of_molecular_genetic_t" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Noonan Syndrome with Multiple Lentigines</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_2">Proportion of NSML Attributed to Mutation of This Gene</th>
                  <th id="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Variants Detected by Test Method</th>
                </tr>
                <tr>
                  <th headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_3" id="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Sequence analysis&#x000a0;<sup>2</sup></th>
                  <th headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_3" id="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>3</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">PTPN11</italic>
                  </td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">90%</td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_3 hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Nearly 100%&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_3 hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown, none reported&#x000a0;<sup>5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">RAF1</italic>
                  </td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;5%</td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_3 hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Nearly 100%&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_3 hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown, none reported&#x000a0;<sup>5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">BRAF</italic>
                  </td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">2 individuals</td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_3 hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">See footnote 7</td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_3 hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown, none reported&#x000a0;<sup>5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">MAP2K1</italic>
                  </td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1 individual</td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_3 hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">See footnote 8</td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_3 hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown, none reported&#x000a0;<sup>5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>9</sup></td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~5%</td>
                  <td headers="hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_1_3 hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_2_1 hd_h_leopard.T.summary_of_molecular_genetic_t_1_1_2_2" valign="middle" colspan="2" align="left" rowspan="1">NA</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="leopard.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="leopard" object-id="leopard.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="leopard.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="leopard.TF.1.2">
                <label>2. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="leopard.TF.1.3">
                <label>3. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="leopard.TF.1.4">
                <label>4. </label>
                <p>Most pathogenic variants causing NSML are identified in exons 7, 12, and 13 [<xref ref-type="bibr" rid="leopard.REF.digilio.2002.389">Digilio et al 2002</xref>, <xref ref-type="bibr" rid="leopard.REF.legius.2002.571">Legius et al 2002</xref>, <xref ref-type="bibr" rid="leopard.REF.sarkozy.2009.695">Sarkozy et al 2009</xref>].</p>
              </fn>
              <fn id="leopard.TF.1.5">
                <label>5. </label>
                <p>No exon or whole-gene deletion or duplication involving <italic toggle="yes">PTPN11</italic>or <italic toggle="yes">RAF1</italic> has been reported as causative of NSML. Based on the molecular mechanisms implicated in disease pathogenesis, exon or whole-gene deletions or duplications are not expected to cause NSML.</p>
              </fn>
              <fn id="leopard.TF.1.6">
                <label>6. </label>
                <p>Sequence analysis of coding exons 6, 13, and 16 detects all reported missense mutations [<xref ref-type="bibr" rid="leopard.REF.pandit.2007.1007">Pandit et al 2007</xref>].</p>
              </fn>
              <fn id="leopard.TF.1.7">
                <label>7. </label>
                <p>Sequence analysis of all coding exons detected missense mutations in two individuals with clinical features of NSML [<xref ref-type="bibr" rid="leopard.REF.sarkozy.2009.695">Sarkozy et al 2009</xref>, <xref ref-type="bibr" rid="leopard.REF.koudova.2009.337">Koudova et al 2009</xref>].</p>
              </fn>
              <fn id="leopard.TF.1.8">
                <label>8. </label>
                <p>Sequence analysis of all coding exons detected missense mutations in one individual with clinical features of NSML [<xref ref-type="bibr" rid="leopard.REF.nishi.2015.407">Nishi et al 2015</xref>].</p>
              </fn>
              <fn id="leopard.TF.1.9">
                <label>9. </label>
                <p>It is likely that one or more additional, as-yet undefined genes, possibly related to RAS signal transduction, are associated with the ~5% of individuals with NSML in whom no pathogenic variant has been identified in <italic toggle="yes">PTPN11</italic>, <italic toggle="yes">RAF1,</italic> or <italic toggle="yes">BRAF</italic>.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="leopard.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="leopard.Clinical_Description">
          <title>Clinical Description</title>
          <p>Males are more likely than females to be affected with Noonan syndrome with multiple lentigines (NSML) [<xref ref-type="bibr" rid="leopard.REF.voron.1976.447">Voron et al 1976</xref>], either as a result of bias of ascertainment or preferential survival of affected male fetuses, as proposed for <related-object link-type="booklink" source-id="gene" document-id="noonan" document-type="chapter">Noonan syndrome</related-object> (NS) [<xref ref-type="bibr" rid="leopard.REF.tartaglia.2004a.492">Tartaglia et al 2004a</xref>].</p>
          <p><bold>Dermatologic.</bold> Multiple lentigines present as dispersed flat, black-brown macules, mostly on the face, neck, and upper part of the trunk with sparing of the mucosa. In general, lentigines do not appear until age four to five years but then increase into the thousands by puberty [<xref ref-type="bibr" rid="leopard.REF.coppin.1997.582">Coppin &#x00026; Temple 1997</xref>]. Some individuals with NSML do not exhibit lentigines.</p>
          <p>Caf&#x000e9; au lait macules are also observed in up to 70%-80% of affected individuals [<xref ref-type="bibr" rid="leopard.REF.digilio.2006.740">Digilio et al 2006</xref>], usually preceding the appearance of lentigines.</p>
          <p>Skin hyperelasticity has also been described.</p>
          <p><bold>Cardiovascular.</bold> Approximately 85% of affected individuals have heart defects, which are similar to those observed in NS but with different frequencies [<xref ref-type="bibr" rid="leopard.REF.limongelli.2007.736">Limongelli et al 2007</xref>].</p>
          <p>Hypertrophic cardiomyopathy is detected in up to 70% of individuals with heart defects (compared to 25% in NS). It most commonly appears during infancy and can be progressive.</p>
          <p>Pulmonary valve stenosis is noted in approximately 25% of affected individuals. Abnormalities of the aortic and mitral valves are also observed in a minority of persons with NSML.</p>
          <p>ECG abnormalities, aside from those typically associated with hypertrophic cardiomyopathy, include conduction defects (23%).</p>
          <p><bold>Facial features.</bold> Dysmorphic facial features are similar to those seen in Noonan syndrome, although usually milder [<xref ref-type="bibr" rid="leopard.REF.digilio.2006.740">Digilio et al 2006</xref>]. Features include inverted triangular-shaped face, downslanted palpebral fissures, low-set posteriorly rotated ears with thickened helices, and widely spaced eyes. The neck can be short with excess nuchal skin and a low posterior hairline.</p>
          <p><bold>Hearing.</bold> Sensorineural hearing deficits are present in approximately 20% of persons with NSML. Minimal information is available about the progression of deafness in those with milder degrees of hearing impairment.</p>
          <p><bold>Growth.</bold> Birth weight is usually normal but may be above the 97th percentile. Postnatal growth retardation resulting in short stature is noted in fewer than 50% of affected individuals, although most have a height that is less than the 25<sup>th</sup> percentile for age. Issues such as adult height and response to growth hormone therapy have not been studied in this disorder.</p>
          <p><bold>Psychomotor development.</bold> Intellectual disability, typically mild, is observed in approximately 30% of persons with NSML. Specific information concerning the deficits typically found in these children is not available.</p>
          <p><bold>Genitourinary.</bold> Cryptorchidism, unilateral or bilateral, is present in approximately one third of affected males. Other abnormalities including hypospadias, urinary tract defects, and ovarian abnormalities are observed infrequently.</p>
        </sec>
        <sec id="leopard.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No clear-cut genotype-phenotype correlations have been observed among the <italic toggle="yes">PTPN11</italic> pathogenic variants causing NSML.</p>
          <p>The two <italic toggle="yes">RAF1</italic> pathogenic variants observed in NSML (see <xref ref-type="table" rid="leopard.T.raf1_pathogenic_allelic_varian">Table 3</xref>) reside in mutational hot spots strongly associated with hypertrophic cardiomyopathy [<xref ref-type="bibr" rid="leopard.REF.pandit.2007.1007">Pandit et al 2007</xref>]. Of note, the <xref ref-type="table" rid="leopard.T.raf1_pathogenic_allelic_varian">p.Ser257Leu</xref> pathogenic variant was associated with both NS and NSML [<xref ref-type="bibr" rid="leopard.REF.pandit.2007.1007">Pandit et al 2007</xref>].</p>
          <p>In addition to NSML in two persons, one third of persons with NS and a <italic toggle="yes">RAF1</italic> pathogenic variant had other findings including multiple nevi, lentigines, and/or caf&#x000e9;-au-lait spots, suggesting a predisposition to hyperpigmented cutaneous lesions associated with these pathogenic variants.</p>
          <p><xref ref-type="bibr" rid="leopard.REF.koudova.2009.337">Koudova et al [2009]</xref> reported a person with NSML and normal intelligence who had a novel sequence change in <italic toggle="yes">BRAF</italic>, further illustrating that the phenotypic spectrum caused by <italic toggle="yes">BRAF</italic> pathogenic variants is broader than previously assumed and does not always include intellectual disability.</p>
        </sec>
        <sec id="leopard.Nomenclature">
          <title>Nomenclature</title>
          <p>Noonan syndrome with multiple lentigines (NSML) was referred to as cardiomyopathic lentiginosis in the older medical literature.</p>
          <p>Until recently, NSML was referred to as LEOPARD syndrome but this name is being phased out due to objections from some families with affected children who found the term offensive.</p>
        </sec>
        <sec id="leopard.Penetrance">
          <title>Penetrance</title>
          <p>Penetrance of NSML is difficult to determine because of ascertainment bias and variable expressivity, frequently with subtlety of phenotypic features. Affected adults may be diagnosed only after the birth of a more obviously affected infant.</p>
        </sec>
        <sec id="leopard.Prevalence">
          <title>Prevalence</title>
          <p>The population prevalence of NSML is not known.</p>
        </sec>
      </sec>
      <sec id="leopard.Genetically_Related_Allelic_Diso">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>The phenotypic overlap that occurs in individuals with germline pathogenic variants in genes causing Noonan syndrome with multiple lentigines, Noonan syndrome, and cardiofaciocutaneous syndrome emphasizes that these disorders (previously defined as distinct clinical entities) constitute a phenotypic continuum and yet highlights the usefulness of phenotype-based management:</p>
        <p>
          <bold>
            <italic toggle="yes">PTPN11</italic>
          </bold>
        </p>
        <p><related-object link-type="booklink" source-id="gene" document-id="noonan" document-type="chapter"><bold>Noonan syndrome</bold></related-object>
<bold>(NS)</bold> (short stature, congenital heart defect, broad or webbed neck, pectus deformities, developmental delay of variable degree, cryptorchidism, and characteristic facies) is an autosomal dominant condition with variable expression. It shows significant overlap with NSML, but affected individuals are unlikely to have the profusion of pigmented lesions, lentigines, and caf&#x000e9; au lait patches or to be deaf. Pathogenic variants in exons 2-14 of <italic toggle="yes">PTPN11</italic> have been reported in approximately 50% of individuals with NS. These reports confirm that NSML and NS are allelic conditions but that particular genotype-phenotype correlations exist with certain pathogenic variants in <italic toggle="yes">PTPN11</italic> leading to the pigmentary changes and higher prevalence of HCM observed in NSML. NS is genetically heterogeneous, with pathogenic variants also identified in <italic toggle="yes">KRAS</italic>, <italic toggle="yes">NRAS, SOS1</italic>, <italic toggle="yes">RAF1, BRAF</italic>, and <italic toggle="yes">RIT1</italic> (&#x0003c;20% of cases).</p>
        <p><bold>Noonan-like/multiple giant-cell lesion syndrome (NL/MGCLS)</bold> is characterized by some cardinal features of NS in association with giant cell lesions of bone and soft tissues (<related-object link-type="booklink" source-id="gene" document-id="cherubism" document-type="chapter">cherubism</related-object>). <italic toggle="yes">PTPN11</italic> pathogenic variants have been described in both familial and simplex (i.e., a single occurrence in a family) cases.</p>
        <p><xref ref-type="bibr" rid="leopard.REF.sarkozy.2004.1069">Sarkozy et al [2004]</xref> reported a female whose early phenotype was typical of NS but who over time developed the hearing loss and lentigines characteristic of NSML. Thus, NL/MGCLS may be too limited and inaccurate a term; a variety of <italic toggle="yes">PTPN11</italic> pathogenic variants, some of them programming the phenotype of NS and others the phenotype of NSML, may also program the development of giant cell lesions.</p>
        <p>Overall, NL/MGCLS-associated <italic toggle="yes">PTPN11</italic> pathogenic variants have been observed in individuals with NS, NSML, or cardiofaciocutaneous syndrome (CFCS), including families segregating the trait without any bony involvement. Thus, additional genetic factors may be necessary for the giant cell proliferation to occur. Consistent with this view, this trait is genetically heterogeneous with documented germline pathogenic variants affecting other NS/CFCS-related genes coding for transducers participating in the RAS-MAPK signalling pathway [<xref ref-type="bibr" rid="leopard.REF.beneteau.2009.1216">Beneteau et al 2009</xref>, <xref ref-type="bibr" rid="leopard.REF.hanna.2009.568">Hanna et al 2009</xref>, <xref ref-type="bibr" rid="leopard.REF.neumann.2009.420">Neumann et al 2009</xref>].</p>
        <p><bold>Sporadic tumors (including leukemia and solid tumors)</bold> occurring as single tumors in the absence of any other findings of NSML or Noonan syndrome frequently harbor somatic pathogenic variants in <italic toggle="yes">PTPN11</italic> that are <bold>not</bold> present in the germline; thus, predisposition to these tumors is not heritable. For more details see <xref ref-type="sec" rid="leopard.Molecular_Genetics">Molecular Genetics</xref>, <bold><italic toggle="yes">PTPN11</italic> cancer and benign tumors</bold>.</p>
        <p>
          <bold>
            <italic toggle="yes">RAF1</italic>
          </bold>
        </p>
        <p><related-object link-type="booklink" source-id="gene" document-id="noonan" document-type="chapter"><bold>Noonan syndrome</bold></related-object>
<bold>(NS)</bold> is also associated with <italic toggle="yes">RAF1</italic> germline pathogenic variants, with a prevalence ranging between 5% and 15% [<xref ref-type="bibr" rid="leopard.REF.pandit.2007.1007">Pandit et al 2007</xref>, <xref ref-type="bibr" rid="leopard.REF.razzaque.2007.1013">Razzaque et al 2007</xref>]. <italic toggle="yes">RAF1</italic> pathogenic variants underlying NS or NSML affect residues clustering in three regions of the protein:</p>
        <list list-type="bullet">
          <list-item>
            <p>The N-terminal consensus 14-3-3 recognition sequence (residues 256 to 261; see <xref ref-type="table" rid="leopard.T.raf1_pathogenic_allelic_varian">Table 3</xref>) or adjacent residues in exon 3. Amino acid substitutions within this region account for approximately 70% of all <italic toggle="yes">RAF1</italic> pathogenic variants.</p>
          </list-item>
          <list-item>
            <p>Asp486 and Thr491 are residues within the activation segment region of the kinase domain encoded by exon 13; alterations in these amino acids constitute approximately 15% of <italic toggle="yes">RAF1</italic> pathogenic variants.</p>
          </list-item>
          <list-item>
            <p>Pathogenic variants in two adjacent residues in exon 16 (Ser612 and Leu613; see <xref ref-type="table" rid="leopard.T.raf1_pathogenic_allelic_varian">Table 3</xref>) account for 15% of <italic toggle="yes">RAF1</italic> pathogenic variants. These two residues are located at the C-terminus in proximity of Ser621, a residue that undergoes phosphorylation and is important for the regulation of the catalytic activation of RAF1.</p>
          </list-item>
        </list>
        <p>A large percentage (70%-90%) of persons with NS and a <italic toggle="yes">RAF1</italic> pathogenic variant have hypertrophic cardiomyopathy (HCM), which is significantly higher than the 20% with HCM observed in the general NS population. Moreover, this genotype-phenotype correlation seems to be domain-specific, as HCM appears to be associated with pathogenic variants affecting the region encoding the N-terminal 14-3-3 consensus site or the C-terminus.</p>
        <p><bold>Sporadic solid tumors</bold> occurring as single tumors in the absence of any other findings of NSML or Noonan syndrome frequently harbor somatic pathogenic variants in <italic toggle="yes">RAF1</italic> that are <bold>not</bold> present in the germline; thus, predisposition to these tumors is not heritable. For more details see <xref ref-type="sec" rid="leopard.Molecular_Genetics">Molecular Genetics</xref>, <bold><italic toggle="yes">RAF1</italic> cancer and benign tumors</bold>.</p>
        <p>
          <bold>
            <italic toggle="yes">BRAF</italic>
          </bold>
        </p>
        <p><related-object link-type="booklink" source-id="gene" document-id="cfc" document-type="chapter"><bold>Cardiofaciocutaneous syndrome</bold></related-object>
<bold>(CFCS).</bold> Pathogenic variants in four genes in the MAPK pathway (<italic toggle="yes">BRAF</italic>, <italic toggle="yes">KRAS</italic>, <italic toggle="yes">MAP2K1</italic>, and <italic toggle="yes">MAP2K2</italic>) have been demonstrated in individuals with CFCS [<xref ref-type="bibr" rid="leopard.REF.niihori.2006.294">Niihori et al 2006</xref>, <xref ref-type="bibr" rid="leopard.REF.rodriguezviciana.2006.1287">Rodriguez-Viciana et al 2006</xref>]. <italic toggle="yes">BRAF</italic> is mutated in 50%-75% of persons with CFCS [<xref ref-type="bibr" rid="leopard.REF.niihori.2006.294">Niihori et al 2006</xref>, <xref ref-type="bibr" rid="leopard.REF.rodriguezviciana.2006.1287">Rodriguez-Viciana et al 2006</xref>, <xref ref-type="bibr" rid="leopard.REF.sarkozy.2009.695">Sarkozy et al 2009</xref>].</p>
        <p>CFCS and NSML have similar cardiac findings; however, in CFCS, intellectual disability is usually more severe, with a higher likelihood of structural central nervous system anomalies; more florid skin pathology; and more severe and long-lasting gastrointestinal problems. In CFCS, facial appearance tends to be coarser; dolichocephaly and absent eyebrows are more common; and blue eyes are less common.</p>
        <p>Analysis of the clinical features of persons with CFCS who have a <italic toggle="yes">BRAF</italic> pathogenic variant indicated a wide phenotypic variability, although all displayed typical dysmorphic facies, cardiac defects, and skin and skeletal anomalies. Moderate-to-severe intellectual disability, observed in most, is commonly associated with seizures or hypotonia. Pigmentary changes including caf&#x000e9;-au-lait spots, nevi, and lentigines are common [<xref ref-type="bibr" rid="leopard.REF.niihori.2006.294">Niihori et al 2006</xref>, <xref ref-type="bibr" rid="leopard.REF.rodriguezviciana.2006.1287">Rodriguez-Viciana et al 2006</xref>, <xref ref-type="bibr" rid="leopard.REF.sarkozy.2009.695">Sarkozy et al 2009</xref>].</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="noonan" document-type="chapter"><bold>Noonan syndrome</bold></related-object>
<bold>(NS).</bold>
<italic toggle="yes">BRAF</italic> is rarely mutated in NS (~2% of affected individuals) [<xref ref-type="bibr" rid="leopard.REF.sarkozy.2009.695">Sarkozy et al 2009</xref>]. The <italic toggle="yes">BRAF</italic> pathogenic variants observed in NS largely do not overlap with those occurring in CFCS, suggesting a genotype-phenotype correlation.</p>
        <p><bold>Sporadic solid tumors</bold> occurring as single tumors in the absence of any other findings of NSML frequently harbor somatic pathogenic variants in <italic toggle="yes">BRAF</italic> that are <bold>not</bold> present in the germline; thus, predisposition to these tumors is not heritable. For more details see <xref ref-type="sec" rid="leopard.Molecular_Genetics">Molecular Genetics</xref>, <bold><italic toggle="yes">BRAF</italic> cancer and benign tumors</bold>.</p>
        <p>
          <bold>
            <italic toggle="yes">MAP2K1</italic>
          </bold>
        </p>
        <p><related-object link-type="booklink" source-id="gene" document-id="cfc" document-type="chapter"><bold>Cardiofaciocutaneous syndrome</bold></related-object>
<bold>(CFCS).</bold> Pathogenic variants in <italic toggle="yes">MAP2K1</italic> have been reported in individuals with CFCS [<xref ref-type="bibr" rid="leopard.REF.rodriguezviciana.2006.1287">Rodriguez-Viciana et al 2006</xref>, <xref ref-type="bibr" rid="leopard.REF.nava.2007.763">Nava et al 2007</xref>, <xref ref-type="bibr" rid="leopard.REF.dentici.2009.733">Dentici et al 2009</xref>]. <italic toggle="yes">MAP2K1</italic> is mutated in approximately 10%-15% of individuals with CFCS [<xref ref-type="bibr" rid="leopard.REF.dentici.2009.733">Dentici et al 2009</xref>].</p>
        <p>The clinical features of those with CFCS who have a <italic toggle="yes">MAP2K1</italic> pathogenic variant fall into the &#x02018;classic&#x02019; CFCS phenotype, particularly regarding the presence of dysmorphic features, short stature, ectodermal findings, and cognitive deficits [<xref ref-type="bibr" rid="leopard.REF.rodriguezviciana.2006.1287">Rodriguez-Viciana et al 2006</xref>, <xref ref-type="bibr" rid="leopard.REF.nava.2007.763">Nava et al 2007</xref>, <xref ref-type="bibr" rid="leopard.REF.dentici.2009.733">Dentici et al 2009</xref>].</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="noonan" document-type="chapter"><bold>Noonan syndrome</bold></related-object>
<bold>(NS).</bold>
<italic toggle="yes">MAP2K1</italic> is rarely mutated in NS [<xref ref-type="bibr" rid="leopard.REF.nava.2007.763">Nava et al 2007</xref>, <xref ref-type="bibr" rid="leopard.REF.chen.2014.11473">Chen et al 2014</xref>]. Three affected individuals exhibited a missense mutation (p.Asp67Asn) that had not previously been reported in CFCS, suggesting a genotype-phenotype correlation.</p>
      </sec>
      <sec id="leopard.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Turner syndrome,</bold> found only in females, is distinguished from Noonan syndrome with multiple lentigines (NSML) by demonstration of an X-chromosome abnormality on cytogenetic studies. The characteristic facial features are also distinct, and in Turner syndrome renal anomalies are more common, developmental delay is much less frequently found, and left-sided heart defects are the rule.</p>
        <p>The <bold>Watson syndrome</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/193520">193520</ext-link>) phenotype also overlaps with that of <related-object link-type="booklink" source-id="gene" document-id="nf1" document-type="chapter">neurofibromatosis type 1</related-object> and the two are now known to be allelic. Variably present in both Watson syndrome and NSML are short stature, pulmonary valve stenosis, variable intellectual development, and skin pigment changes including caf&#x000e9; au lait macules. Lentigines are not described in Watson syndrome. Heterozygous pathogenic variants in <italic toggle="yes">NF1</italic> are causative.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="costello" document-type="chapter"><bold>Costello syndrome</bold></related-object>
<bold>(CS)</bold> shares features with NSML, <related-object link-type="booklink" source-id="gene" document-id="noonan" document-type="chapter">NS</related-object>, and <related-object link-type="booklink" source-id="gene" document-id="cfc" document-type="chapter">CFCS</related-object>. Two series of individuals with CS have been studied molecularly and no <italic toggle="yes">PTPN11</italic> pathogenic variant has been identified [<xref ref-type="bibr" rid="leopard.REF.tartaglia.2003a.423">Tartaglia et al 2003a</xref>, <xref ref-type="bibr" rid="leopard.REF.tr_ger.2003.82">Tr&#x000f6;ger et al 2003</xref>]. Germline mutation occurring predominantly in the first and third coding exons of the <italic toggle="yes">HRAS</italic> proto-oncogene has been shown to cause CS [<xref ref-type="bibr" rid="leopard.REF.aoki.2005.1038">Aoki et al 2005</xref>].</p>
        <p><bold>Other.</bold> NSML should be distinguished from other syndromes with developmental delay, short stature, congenital heart defects, and distinctive facies, especially <related-object link-type="booklink" source-id="gene" document-id="williams" document-type="chapter">Williams syndrome</related-object>.</p>
      </sec>
      <sec id="leopard.Management_1">
        <title>Management</title>
        <sec id="leopard.Evaluations_Following_Initial_Di">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Noonan syndrome with multiple lentigines (NSML), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Complete physical and neurologic examination</p>
            </list-item>
            <list-item>
              <p>Plotting of growth parameters on <related-object link-type="booklink" source-id="gene" document-id="noonan" document-type="chapter">Noonan syndrome</related-object> growth charts by <xref ref-type="bibr" rid="leopard.REF.witt.1986.150">Witt et al [1986]</xref> (Specific growth charts for NSML are not available.)</p>
            </list-item>
            <list-item>
              <p>Cardiac evaluation with echocardiography and electrocardiography</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic evaluation</p>
            </list-item>
            <list-item>
              <p>Hearing evaluation including complete assessment of auditory acuity using age-appropriate tests (e.g., ABR testing, auditory steady-state response [ASSR] testing, pure tone audiometry)</p>
            </list-item>
            <list-item>
              <p>Renal ultrasound examination; urinalysis if urinary tract abnormalities are identified</p>
            </list-item>
            <list-item>
              <p>Clinical and radiographic assessment of spine and rib cage</p>
            </list-item>
            <list-item>
              <p>Brain and cervical spine MRI if neurologic symptoms are present</p>
            </list-item>
            <list-item>
              <p>Multidisciplinary developmental evaluation</p>
            </list-item>
            <list-item>
              <p>Consultation with a medical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="leopard.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Treatment of cardiovascular anomalies and cryptorchidism is usually the same as in the general population.</p>
          <p>Treatment of hearing loss may include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Fitting with appropriate hearing aids</p>
            </list-item>
            <list-item>
              <p>Enrollment in an appropriate educational program for the hearing impaired</p>
            </list-item>
            <list-item>
              <p>Consideration for cochlear implantation, a promising habilitation option for persons with profound deafness</p>
            </list-item>
            <list-item>
              <p>Recognition that, as distinct from many clinical conditions, the management and treatment of severe-to-profound congenital deafness involves primarily the social welfare and educational systems rather than the medical care system [<xref ref-type="bibr" rid="leopard.REF.smith.2005.879">Smith et al 2005</xref>]</p>
            </list-item>
          </list>
          <p>Any developmental disability should be addressed by early intervention programs and individualized education strategies.</p>
          <p>Treatment of cryptorchidism in males is usually the same as in the general population.</p>
        </sec>
        <sec id="leopard.Prevention_of_Secondary_Complica">
          <title>Prevention of Secondary Complications</title>
          <p>For individuals with hypertrophic cardiomyopathy, certain physical activities may be curtailed in order to reduce the risk of sudden cardiac death.</p>
          <p>For individuals diagnosed in infancy, early intervention may limit the extent of intellectual and developmental disabilities.</p>
        </sec>
        <sec id="leopard.Surveillance">
          <title>Surveillance</title>
          <p>If anomalies are found in any system, periodic follow up should be planned and lifelong monitoring may be necessary, especially of cardiovascular abnormalities.</p>
          <p>For hearing loss, twice-yearly examination by a physician familiar with hereditary hearing impairment and repeat audiometry to confirm the stability of the hearing loss is recommended.</p>
          <p>Surveillance for intellectual and developmental disabilities as per routine pediatric care is of particular importance due to the higher prevalence of these issues in individuals with NSML.</p>
          <p>Surveillance for growth delay as per routine pediatric care is important due to the higher prevalence of poor linear growth in affected children.</p>
        </sec>
        <sec id="leopard.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>For individuals with hypertrophic cardiomyopathy, treatment with growth hormone must be undertaken with great caution, if at all, to avoid exacerbating a cardiac condition.</p>
        </sec>
        <sec id="leopard.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate relatives at risk in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures.</p>
          <list list-type="bullet">
            <list-item>
              <p>If the <italic toggle="yes">PTPN11</italic>, <italic toggle="yes">RAF1,</italic>
<italic toggle="yes">BRAF</italic>, or <italic toggle="yes">MAP2K1</italic> pathogenic variant in the family is known, molecular genetic testing can be used to clarify the genetic status of at-risk relatives.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant in the family is not known, a thorough physical examination with particular attention to the features of NSML may clarify the disease status of at-risk relatives.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="leopard.Related_Genetic_Counseling_Issue">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="leopard.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>For affected women, cardiac status should be monitored during pregnancy. Those with hypertrophic cardiomyopathy or valve dysfunction may be at risk for the development or exacerbation of heart failure during pregnancy, especially during the second and third trimesters.</p>
        </sec>
        <sec id="leopard.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="leopard.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="leopard.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Noonan syndrome with multiple lentigines (NSML) is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="leopard.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Some individuals diagnosed with NSML have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with NSML may have the disorder as the result of a <italic toggle="yes">de novo</italic>
<italic toggle="yes">PTPN11</italic>, <italic toggle="yes">RAF1,</italic>
<italic toggle="yes">BRAF,</italic> or <italic toggle="yes">MAP2K1</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the DNA of either parent, two possible explanations are germline mosaicism in a parent or <italic toggle="yes">de novo</italic> mutation in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include a thorough physical examination with particular attention to the features of NSML.</p>
            </list-item>
            <list-item>
              <p>The family history of some individuals diagnosed with NSML may appear to be negative because of failure to recognize the disorder in family members. Therefore, an apparently negative family history cannot be confirmed unless appropriate evaluations and molecular genetic testing has been performed on the parents of the proband</p>
            </list-item>
          </list>
          <p>Note: If the parent is the individual in whom the pathogenic variant first occurred s/he may have somatic mosaicism for the pathogenic variant and may be mildly/minimally affected.</p>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">PTPN11</italic>, <italic toggle="yes">RAF1,</italic>
<italic toggle="yes">BRAF,</italic> or <italic toggle="yes">MAP2K1</italic> pathogenic variant found in the proband cannot be detected in the DNA of either parent, the risk to sibs is low but greater than that of the general population because of the possibility of germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with NSML has a 50% chance of inheriting the pathogenic variant.</p>
          <p>
            <bold>Other family members of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent is affected, his or her family members may be at risk.</p>
            </list-item>
          </list>
        </sec>
        <sec id="leopard.Related_Genetic_Counseling_Issue">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="leopard.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with NSML has the pathogenic variant, the <italic toggle="yes">PTPN11</italic>, <italic toggle="yes">RAF1,</italic>
<italic toggle="yes">BRAF,</italic> or <italic toggle="yes">MAP2K1</italic> pathogenic variant is likely <italic toggle="yes">de novo</italic>. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="leopard.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the <italic toggle="yes">PTPN11</italic>, <italic toggle="yes">RAF1,</italic>
<italic toggle="yes">BRAF,</italic> or <italic toggle="yes">MAP2K1</italic> pathogenic variant has been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of this gene or custom prenatal testing.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">PTPN11</italic>, <italic toggle="yes">RAF1,</italic>
<italic toggle="yes">BRAF,</italic> or <italic toggle="yes">MAP2K1</italic> pathogenic variant has been identified.</p>
        </sec>
      </sec>
      <sec id="leopard.Resources">
        <title>Resources</title>
      </sec>
      <sec id="leopard.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p>
          <bold>
            <italic toggle="yes">PTPN11</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold> The gene has 15 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="leopard" object-id="leopard.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold> See <xref ref-type="table" rid="leopard.T.selected_ptpn11_pathogenic_all">Table 2</xref>. Missense mutations in <italic toggle="yes">PTPN11</italic> were identified in 90% of individuals with Noonan syndrome with multiple lentigines (NSML) examined. Pathogenic variants alter residues at or close to the N-SH2/PTP interacting surfaces, which are involved in switching between active and inactive conformations of the protein, and participating in catalysis. Biochemical characterization of a panel of mutants documented that NSML-associated pathogenic variants impair catalytic activity [<xref ref-type="bibr" rid="leopard.REF.hanna.2006.2477">Hanna et al 2006</xref>, <xref ref-type="bibr" rid="leopard.REF.kontaridis.2006.6785">Kontaridis et al 2006</xref>, <xref ref-type="bibr" rid="leopard.REF.tartaglia.2006.279">Tartaglia et al 2006</xref>].</p>
        <table-wrap id="leopard.T.selected_ptpn11_pathogenic_all" position="anchor" orientation="portrait">
          <label>Table 2. </label>
          <caption>
            <p>Selected <italic toggle="yes">PTPN11</italic> Pathogenic Allelic Variants of Interest Including Those Causing Noonan Syndrome with Multiple Lentigines</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                <th id="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.836A&#x0003e;G</td>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr279Cys</td>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_3" rowspan="9" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/33356176">NM_002834.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/33356177">NP_002825.3</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.836A&#x0003e;C</td>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr279Ser</td>
              </tr>
              <tr>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1381G&#x0003e;A</td>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala461Thr</td>
              </tr>
              <tr>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1391G&#x0003e;C</td>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly464Ala</td>
              </tr>
              <tr>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1403C&#x0003e;T</td>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr468Met</td>
              </tr>
              <tr>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1492C&#x0003e;T</td>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg498Leu</td>
              </tr>
              <tr>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1493G&#x0003e;T</td>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg498Trp</td>
              </tr>
              <tr>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1517A&#x0003e;C</td>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln506Pro</td>
              </tr>
              <tr>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1528C&#x0003e;G</td>
                <td headers="hd_h_leopard.T.selected_ptpn11_pathogenic_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln510Glu</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">PTPN11</italic> encodes tyrosine-protein phosphatase non-receptor type 11 (also known as protein tyrosine phosphatase non-receptor type 11, or SHP-2), a widely expressed intracellular protein. The protein is a key molecule in the cellular response to growth factors, hormones, cytokines, and cell adhesion molecules [<xref ref-type="bibr" rid="leopard.REF.neel.2003.284">Neel et al 2003</xref>]. It is required in several intracellular signal transduction pathways that control diverse developmental processes (including cardiac semilunar valvulogenesis and blood cell progenitor commitment and differentiation) and has a role in modulating cellular proliferation, differentiation, migration, and apoptosis. The protein has two tandemly arranged SRC-homology 2 (SH2) domains at the N-terminus (N-SH2 and C-SH2), a single catalytic protein tyrosine phosphatase (PTP) domain, and a C-terminal tail with two tyrosyl phosphorylation sites and a proline-rich stretch. The N-SH2-PTP interaction maintains the protein in an inactive state.</p>
        <p><bold>Abnormal gene product.</bold> Aberrant function of SHP-2 causes dysregulation of growth factor and cytokine-mediated RAS/ERK/MAPK and PI3K/AKT signal flow, perturbing cell proliferation [<xref ref-type="bibr" rid="leopard.REF.fragale.2004.267">Fragale et al 2004</xref>, <xref ref-type="bibr" rid="leopard.REF.chan.2005.3737">Chan et al 2005</xref>, <xref ref-type="bibr" rid="leopard.REF.keilhack.2005.30984">Keilhack et al 2005</xref>, <xref ref-type="bibr" rid="leopard.REF.hanna.2006.2477">Hanna et al 2006</xref>, <xref ref-type="bibr" rid="leopard.REF.kontaridis.2006.6785">Kontaridis et al 2006</xref>].</p>
        <p><bold>Leukemia and solid tumors.</bold> Juvenile myelomonocytic leukemia (JMML) accounts for one third of childhood cases of myelodysplastic syndrome (MDS) and about 2% of leukemia. Pathogenic variants in <italic toggle="yes">NRAS, KRAS</italic>, and <italic toggle="yes">NF1</italic> have been shown to deregulate the RAS/MAPK pathway leading to JMML in about 40% of cases. Somatic pathogenic variants in exons 3 and 13 of <italic toggle="yes">PTPN11</italic> have been demonstrated in 34% of a cohort of individuals with JMML [<xref ref-type="bibr" rid="leopard.REF.tartaglia.2003b.148">Tartaglia et al 2003b</xref>]. Pathogenic variants in exon 3 were also found in 19% of children with MDS with an excess of blast cells, which often evolves into acute myeloid leukemia (AML) and is associated with poor prognosis. Nonsyndromic AML, especially the monocyte subtype FAB-M5, has been shown to be caused by <italic toggle="yes">PTPN11</italic> pathogenic variants. All of these pathogenic variants result in a gain of function of the protein tyrosine phosphatase non-receptor type 11 (SHP-2), likely leading to an early initiating lesion in JMML oncogenesis with increased cell proliferation attributable, in part, to prolonged activation of the RAS/MAPK pathway.</p>
        <p>The spectrum of leukemogenesis associated with <italic toggle="yes">PTPN11</italic> pathogenic variants has been extended to include childhood acute lymphoblastic leukemia (ALL). Pathogenic variants were observed in 8% of B-cell precursor ALL cases, but not among children with T-lineage ALL [<xref ref-type="bibr" rid="leopard.REF.tartaglia.2004b.307">Tartaglia et al 2004b</xref>]. Additionally, SHP-2-activating <italic toggle="yes">PTPN11</italic> pathogenic variants have been found rarely in solid tumors including breast, lung, and gastric neoplasms and neuroblastoma [<xref ref-type="bibr" rid="leopard.REF.bentiresalj.2004.8816">Bentires-Alj et al 2004</xref>].</p>
        <p>
          <bold>
            <italic toggle="yes">RAF1</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">RAF1</italic> comprises 17 exons. It has three conserved regions (CR): CR1, encoded by exons 2-5, contains a RAS-binding domain (RBD) and a cysteine-rich domain (CRD); CR2 is encoded by exon 7; CR3, encoded by exons 10-17, contains the kinase domain and its regulatory element, the activation segment. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="leopard" object-id="leopard.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold> See <xref ref-type="table" rid="leopard.T.raf1_pathogenic_allelic_varian">Table 3</xref>. The consensus 14-3-3 recognition site includes residues Arg256, Ser257, Ser259, and Pro261, and is encoded by exon 7 (coding exon 6). One pathogenic variant identified in NSML (p.Ser257Leu) altered this CR2 domain, interfered with 14-3-3 binding, and caused greater kinase activity than wild-type protein, both basally and after stimulation [<xref ref-type="bibr" rid="leopard.REF.pandit.2007.1007">Pandit et al 2007</xref>].</p>
        <p>The other NSML-associated pathogenic variant, p.Leu613Val, altered the C-terminal portion of RAF1 (coding exon 16). This pathogenic variant also caused greater kinase activity than wild-type protein, both basally and after EGF stimulation.</p>
        <table-wrap id="leopard.T.raf1_pathogenic_allelic_varian" position="anchor" orientation="portrait">
          <label>Table 3. </label>
          <caption>
            <p><italic toggle="yes">RAF1</italic> Pathogenic Allelic Variants of Interest Including Those Causing Noonan Syndrome with Multiple Lentigines</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_leopard.T.raf1_pathogenic_allelic_varian_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_leopard.T.raf1_pathogenic_allelic_varian_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                <th id="hd_h_leopard.T.raf1_pathogenic_allelic_varian_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequence</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_leopard.T.raf1_pathogenic_allelic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.770C&#x0003e;T</td>
                <td headers="hd_h_leopard.T.raf1_pathogenic_allelic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ser257Leu</td>
                <td headers="hd_h_leopard.T.raf1_pathogenic_allelic_varian_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/52486392">NM_002880.2</ext-link>
<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/4506401">NP_002871.1</ext-link></td>
              </tr>
              <tr>
                <td headers="hd_h_leopard.T.raf1_pathogenic_allelic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1837C&#x0003e;G</td>
                <td headers="hd_h_leopard.T.raf1_pathogenic_allelic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu613Val</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">RAF1</italic> is ubiquitously expressed and encodes a protein of 648 amino acids with three domains. CR1 contains a Ras-binding domain; CR2 is a site of regulatory phosphorylation and association with the 14-3-3 protein. CR1 and CR2 both have negative regulatory function, removal of which results in oncogenic activity. The kinase domain, CR3, also associates with 14-3-3.</p>
        <p>The protein is highly regulated with numerous serine and threonine residues that can be phosphorylated, resulting in activation or inactivation. The serine at residue 259, which is in CR2, is particularly important. In the inactive state, the N-terminus of RAF1 interacts with and inactivates the kinase domain at the C-terminus. This conformation is stabilized by 14-3-3 protein dimers that bind to phosphorylated Ser259 and Ser261. Dephosphorylation of Ser259 facilitates binding of RAF1 to RAS-GTP and propagation of the signal through the RAS-MAPK cascade via RAF1 MEK kinase activity.</p>
        <p><bold>Abnormal gene product.</bold> NSML-associated <italic toggle="yes">RAF1</italic> pathogenic variants increase and prolong RAS downstream signaling through enhanced kinase activity, leading to increased activation of MAP kinase kinases (<italic toggle="yes">MAP2K1</italic> and <italic toggle="yes">MAP2K2</italic>).</p>
        <p><bold><italic toggle="yes">RAF1</italic> cancer and benign tumors.</bold> Almost none of the <italic toggle="yes">RAF1</italic> residues mutated in NS (and NSML) are altered in cancer.</p>
        <p>
          <bold>
            <italic toggle="yes">BRAF</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold> The gene has 18 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="leopard" object-id="leopard.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold> Two germline missense changes affecting exon 6 have been reported in two persons with a diagnosis of NSML (see <xref ref-type="table" rid="leopard.T.braf_pathogenic_allelic_varian">Table 4</xref>) [<xref ref-type="bibr" rid="leopard.REF.koudova.2009.337">Koudova et al 2009</xref>, <xref ref-type="bibr" rid="leopard.REF.sarkozy.2009.695">Sarkozy et al 2009</xref>].</p>
        <table-wrap id="leopard.T.braf_pathogenic_allelic_varian" position="anchor" orientation="portrait">
          <label>Table 4. </label>
          <caption>
            <p><italic toggle="yes">BRAF</italic> Pathogenic Allelic Variants Causing Noonan Syndrome with Multiple Lentigines</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_leopard.T.braf_pathogenic_allelic_varian_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_leopard.T.braf_pathogenic_allelic_varian_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                <th id="hd_h_leopard.T.braf_pathogenic_allelic_varian_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequence</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_leopard.T.braf_pathogenic_allelic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.721A&#x0003e;C</td>
                <td headers="hd_h_leopard.T.braf_pathogenic_allelic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr241Pro</td>
                <td headers="hd_h_leopard.T.braf_pathogenic_allelic_varian_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/187608632">NM_004333.4</ext-link>
<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/33188459">NP_004324.2</ext-link></td>
              </tr>
              <tr>
                <td headers="hd_h_leopard.T.braf_pathogenic_allelic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.735A&#x0003e;T</td>
                <td headers="hd_h_leopard.T.braf_pathogenic_allelic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu245Phe</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> Exons 3-6, encode a RAS-binding domain (RBD) and a cysteine-rich domain (CRD), while the kinase domain is encoded by exons 11-17. <italic toggle="yes">BRAF</italic> is ubiquitously expressed and encodes a protein of 766 amino acids. It is activated following GTP-bound RAS binding, and phosphorylates and activates the dual specificity mitogen-activated protein kinase kinases (<italic toggle="yes">MAP2K1</italic> and <italic toggle="yes">MAP2K2</italic>).</p>
        <p><bold>Abnormal gene product.</bold> The NSML-associated p.Thr241Pro <italic toggle="yes">BRAF</italic> pathogenic variant enhances RAS signaling through increased activation of MEK and ERK kinases [<xref ref-type="bibr" rid="leopard.REF.sarkozy.2009.695">Sarkozy et al 2009</xref>]. NIH-3T3 cell colony focus formation assay data indicate that associated (p.Thr241Pro) BRAF mutants do not confer enhanced transformation to cells [<xref ref-type="bibr" rid="leopard.REF.sarkozy.2009.695">Sarkozy et al 2009</xref>].</p>
        <p><bold><italic toggle="yes">BRAF</italic> cancer and benign tumors.</bold>
<italic toggle="yes">BRAF</italic> variants mutated in solid tumors (p.Asp594Gly and p.Thr599Ile) alter the functional activation segment [<xref ref-type="bibr" rid="leopard.REF.pandit.2007.1007">Pandit et al 2007</xref>].</p>
        <p>Note: No occurrence of the common <italic toggle="yes">BRAF</italic> oncogenic somatic p.Val600Glu amino acid substitution has been documented to occur as a germline event associated with CFCS, NS, or NSML.</p>
        <p>
          <bold>
            <italic toggle="yes">MAP2K1</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold> The gene has 11 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="leopard" object-id="leopard.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold> One germline missense mutation affecting exon 2,the variant c.305A&#x0003e;G (p.Glu102Gly), has been reported in one subject with a diagnosis of NSML (see <xref ref-type="table" rid="leopard.T.map2k1_pathogenic_allelic_vari">Table 5</xref>) [<xref ref-type="bibr" rid="leopard.REF.nishi.2015.407">Nishi et al 2015</xref>].</p>
        <table-wrap id="leopard.T.map2k1_pathogenic_allelic_vari" position="anchor" orientation="portrait">
          <label>Table 5. </label>
          <caption>
            <p><italic toggle="yes">MAP2K1</italic> Pathogenic Allelic Variants of Interest Including Those Causing Noonan Syndrome with Multiple Lentigines</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_leopard.T.map2k1_pathogenic_allelic_vari_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_leopard.T.map2k1_pathogenic_allelic_vari_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                <th id="hd_h_leopard.T.map2k1_pathogenic_allelic_vari_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequence</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_leopard.T.map2k1_pathogenic_allelic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.199G&#x0003e;A</td>
                <td headers="hd_h_leopard.T.map2k1_pathogenic_allelic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asp67Asn</td>
                <td headers="hd_h_leopard.T.map2k1_pathogenic_allelic_vari_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">NM_002755.3<break/>NP_002746.1</td>
              </tr>
              <tr>
                <td headers="hd_h_leopard.T.map2k1_pathogenic_allelic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.305A&#x0003e;G</td>
                <td headers="hd_h_leopard.T.map2k1_pathogenic_allelic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu102Gly</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> Exon 2 encodes the N-terminal portion of the catalytic domain. The gene is widely expressed and encodes a protein of 393 amino acid residues. MAP2K1 is a dual specificity protein kinase. It is activated following phosphorylation by kinases of the RAF family, and phosphorylates and activates the mitogen-activated protein kinases (MAP1K1 and MAP1K2).</p>
        <p><bold>Abnormal gene product.</bold> The NSML-associated p.Glu102Gly <italic toggle="yes">MAP2K1</italic> variant has not been characterized biochemically or functionally, but is predicted to enhance signaling through the MAPK cascade.</p>
      </sec>
      <sec id="leopard.References">
        <title>References</title>
        <sec id="leopard.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="leopard.Literature_Cited.reflist0">
            <ref id="leopard.REF.aoki.2005.1038">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aoki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niihori</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawame</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurosawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohashi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filocamo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kure</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsubara</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Germline mutations in HRAS proto-oncogene cause Costello syndrome.</article-title>
                <source>Nat Genet</source>
                <volume>37</volume>
                <fpage>1038</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">16170316</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.beneteau.2009.1216">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beneteau</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cav&#x000e9;</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moncla</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dorison</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verloes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leheup</surname>
                    <given-names>B.</given-names>
                  </name>
                </person-group>
                <article-title>SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2009</year>
                <month>Oct</month>
                <volume>17</volume>
                <issue>10</issue>
                <fpage>1216</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">19352411</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.bentiresalj.2004.8816">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bentires-Alj</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paez</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>David</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keilhack</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halmos</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naoki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maris</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richardson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bardelli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugarbaker</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Du</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girard</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minna</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loh</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fisher</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Velculescu</surname>
                    <given-names>VE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogelstein</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyerson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sellers</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neel</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.</article-title>
                <source>Cancer Res</source>
                <volume>64</volume>
                <fpage>8816</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">15604238</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.chan.2005.3737">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leedy</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munugalavadla</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voorhorst</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kapur</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.</article-title>
                <source>Blood</source>
                <volume>105</volume>
                <fpage>3737</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">15644411</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.chen.2014.11473">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>HW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuan</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yung</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trinh</surname>
                    <given-names>QM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peltekova</surname>
                    <given-names>VD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reid</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tworog-Dube</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muzny</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stein</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McPherson</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibbs</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neel</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kucherlapati</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Next-generation sequencing identifies rare variants associated with Noonan syndrome.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <year>2014</year>
                <month>Aug</month>
                <day>5</day>
                <volume>111</volume>
                <issue>31</issue>
                <fpage>11473</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">25049390</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.coppin.1997.582">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coppin</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Temple</surname>
                    <given-names>IK</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Multiple lentigines syndrome (LEOPARD syndrome or progressive cardiomyopathic lentiginosis).</article-title>
                <source>J Med Genet</source>
                <volume>34</volume>
                <fpage>582</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">9222968</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.dentici.2009.733">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dentici</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarkozy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pantaleoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carta</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lepri</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferese</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordeddu</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briuglia</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Digilio</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zampino</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tartaglia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dallapiccola</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>17</volume>
                <fpage>733</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">19156172</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.digilio.2002.389">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Digilio</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarkozy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mingarelli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dottorini</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marino</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pizzuti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dallapiccola</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene.</article-title>
                <source>Am J Hum Genet</source>
                <volume>71</volume>
                <fpage>389</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">12058348</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.digilio.2006.740">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Digilio</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarkozy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Zorzi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacileo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Limongelli</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mingarelli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calabro</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marino</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dallapiccola</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>LEOPARD syndrome: clinical diagnosis in the first year of life.</article-title>
                <source>Am J Med Genet A</source>
                <volume>140</volume>
                <fpage>740</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16523510</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.fragale.2004.267">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fragale</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tartaglia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelb</surname>
                    <given-names>BD</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.</article-title>
                <source>Hum Mutat</source>
                <volume>23</volume>
                <fpage>267</fpage>
                <lpage>77</lpage>
                <pub-id pub-id-type="pmid">14974085</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.hanna.2006.2477">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montagner</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miteva</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vidal</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vidaud</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parfait</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raynal</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1.</article-title>
                <source>FEBS Lett</source>
                <volume>580</volume>
                <fpage>2477</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">16638574</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.hanna.2009.568">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parfait</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Talaat</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vidaud</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elsedfy</surname>
                    <given-names>HH</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>SOS1: a new player in the Noonan-like/multiple giant cell lesion syndrome.</article-title>
                <source>Clin Genet</source>
                <volume>75</volume>
                <fpage>568</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">19438935</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.keilhack.2005.30984">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Keilhack</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>David</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGregor</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cantley</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neel</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.</article-title>
                <source>J Biol Chem</source>
                <volume>280</volume>
                <fpage>30984</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">15987685</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.kontaridis.2006.6785">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kontaridis</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swanson</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>David</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barford</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neel</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.</article-title>
                <source>J Biol Chem</source>
                <volume>281</volume>
                <fpage>6785</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">16377799</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.koudova.2009.337">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koudova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seemanova</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zenker</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Novel BRAF mutation in a patient with LEOPARD syndrome and normal intelligence.</article-title>
                <source>Eur J Med Genet</source>
                <volume>52</volume>
                <fpage>337</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">19416762</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.legius.2002.571">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Legius</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schrander-Stumpel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schollen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulles-Heintzberger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gewillig</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fryns</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>PTPN11 mutations in LEOPARD syndrome.</article-title>
                <source>J Med Genet</source>
                <volume>39</volume>
                <fpage>571</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">12161596</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.limongelli.2007.736">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Limongelli</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacileo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marino</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Digilio</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarkozy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Versacci</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calabro</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Zorzi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Salvo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Syrris</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patton</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKenna</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dallapiccola</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calabro</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome.</article-title>
                <source>Am J Cardiol</source>
                <volume>100</volume>
                <fpage>736</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">17697839</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.nava.2007.763">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nava</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michot</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pereira</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pouvreau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niihori</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aoki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsubara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arveiler</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasmant</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parfait</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000e9;ron</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sigaudy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toutain</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldenberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leheup</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verloes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cav&#x000e9;</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.</article-title>
                <source>J Med Genet</source>
                <volume>44</volume>
                <fpage>763</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">17704260</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.neel.2003.284">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neel</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pao</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.</article-title>
                <source>Trends Biochem Sci</source>
                <volume>28</volume>
                <fpage>284</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">12826400</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.neumann.2009.420">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>TE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allanson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kavamura</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerr</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neri</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noonan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordeddu</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tzschach</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kr&#x000fc;ger</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoeltzenbein</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goecke</surname>
                    <given-names>TO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kehl</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Albrecht</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luczak</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasiadek</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Musante</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laurie</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tartaglia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zenker</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalscheuer</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome.</article-title>
                <source>Eur J Hum Genet.</source>
                <volume>17</volume>
                <fpage>420</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">18854871</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.niihori.2006.294">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Niihori</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aoki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Narumi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neri</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cave</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verloes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okamoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hennekam</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillessen-Kaesbach</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wieczorek</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kavamura</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurosawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohashi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heron</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonneau</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corona</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaname</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naritomi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsumoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kure</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsubara</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.</article-title>
                <source>Nat Genet</source>
                <volume>38</volume>
                <fpage>294</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16474404</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.nishi.2015.407">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nishi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizuno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nanjo</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niihori</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukushima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsubara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aoki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kosho</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>A novel heterozygous MAP2K1 mutation in a patient with Noonan syndrome with multiple lentigines.</article-title>
                <source>Am J Med Genet A</source>
                <volume>167A</volume>
                <fpage>407</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">25423878</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.pandit.2007.1007">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pandit</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarkozy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pennacchio</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carta</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oishi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pogna</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schackwitz</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ustaszewska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landstrom</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bos</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ommen</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esposito</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lepri</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faul</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mundel</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopez Siguero</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tenconi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Selicorni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzanti</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torrente</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marino</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Digilio</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zampino</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackerman</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dallapiccola</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tartaglia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelb</surname>
                    <given-names>BD</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.</article-title>
                <source>Nat Genet</source>
                <volume>39</volume>
                <fpage>1007</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">17603483</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.razzaque.2007.1013">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Razzaque</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishizawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komoike</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yagi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furutani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamisago</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Momma</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katayama</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakagawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiwara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsushima</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizuno</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokuyama</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirota</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muneuchi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higashinakagawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuoka</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Germline gain-of-function mutations in RAF1 cause Noonan syndrome.</article-title>
                <source>Nat Genet.</source>
                <volume>39</volume>
                <fpage>1013</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17603482</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.rodriguezviciana.2006.1287">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rodriguez-Viciana</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tetsu</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tidyman</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estep</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conger</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cruz</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCormick</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rauen</surname>
                    <given-names>KA</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.</article-title>
                <source>Science</source>
                <volume>311</volume>
                <fpage>1287</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">16439621</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.sarkozy.2009.695">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sarkozy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carta</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moretti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zampino</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Digilio</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pantaleoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scioletti</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esposito</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordeddu</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lepri</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrangeli</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dentici</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Selicorni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzanti</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marino</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrero</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silengo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Memo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanzial</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faravelli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuppia</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puxeddu</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelb</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dallapiccola</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tartaglia</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.</article-title>
                <source>Hum Mutat</source>
                <volume>30</volume>
                <fpage>695</fpage>
                <lpage>702</lpage>
                <pub-id pub-id-type="pmid">19206169</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.sarkozy.2004.1069">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sarkozy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Obregon</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esposito</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mingarelli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pizzuti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dallapiccola</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>A novel PTPN11 gene mutation bridges Noonan syndrome, multiple lentigines/LEOPARD syndrome and Noonan-like/multiple giant cell lesion syndrome.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>12</volume>
                <fpage>1069</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">15470362</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.sarkozy.2008.13">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sarkozy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Digilio</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dallapiccola</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Leopard syndrome.</article-title>
                <source>Orphanet J Rare Dis</source>
                <volume>3</volume>
                <fpage>13</fpage>
                <pub-id pub-id-type="pmid">18505544</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.smith.2005.879">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bale</surname>
                    <given-names>JF</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>KR</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Sensorineural hearing loss in children.</article-title>
                <source>Lancet</source>
                <volume>365</volume>
                <fpage>879</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">15752533</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.tartaglia.2004a.492">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tartaglia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordeddu</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaw</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalidas</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crosby</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patton</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorcini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Burgt</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffery</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelb</surname>
                    <given-names>BD</given-names>
                  </name>
                </person-group>
                <year>2004a</year>
                <article-title>Paternal germline origin and sex-ratio distortion in transmission of PTPN11 mutations in Noonan syndrome.</article-title>
                <source>Am J Hum Genet</source>
                <volume>75</volume>
                <fpage>492</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15248152</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.tartaglia.2003a.423">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tartaglia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cotter</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zampino</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelb</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rauen</surname>
                    <given-names>KA</given-names>
                  </name>
                </person-group>
                <year>2003a</year>
                <article-title>Exclusion of PTPN11 mutations in Costello syndrome: further evidence for distinct genetic etiologies for Noonan, cardio-facio-cutaneous and Costello syndromes.</article-title>
                <source>Clin Genet</source>
                <volume>63</volume>
                <fpage>423</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12752577</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.tartaglia.2004b.307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tartaglia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazzaniga</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordeddu</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iavarone</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spinelli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carta</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pession</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arico</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masera</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basso</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorcini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelb</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biondi</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004b</year>
                <article-title>Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.</article-title>
                <source>Blood</source>
                <volume>104</volume>
                <fpage>307</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">14982869</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.tartaglia.2006.279">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tartaglia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stella</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bocchinfuso</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flex</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordeddu</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zampino</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burgt</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palleschi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrucci</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorcini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foa</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emanuel</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelb</surname>
                    <given-names>BD</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.</article-title>
                <source>Am J Hum Genet</source>
                <volume>78</volume>
                <fpage>279</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">16358218</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.tartaglia.2003b.148">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tartaglia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niemeyer</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fragale</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Song</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buechner</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jung</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hahlen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasle</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Licht</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelb</surname>
                    <given-names>BD</given-names>
                  </name>
                </person-group>
                <year>2003b</year>
                <article-title>Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.</article-title>
                <source>Nat Genet</source>
                <volume>34</volume>
                <fpage>148</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">12717436</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.tr_ger.2003.82">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tr&#x000f6;ger</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kutsche</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolz</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000fc;ttgen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gal</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almassy</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caliebe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freisinger</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hobbiebrunken</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morlot</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stefanova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Streubel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wieczorek</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meinecke</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>No mutation in the gene for Noonan syndrome, PTPN11, in 18 patients with Costello syndrome.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>121A</volume>
                <fpage>82</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">12900909</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.voron.1976.447">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Voron</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hatfield</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalkhoff</surname>
                    <given-names>RK</given-names>
                  </name>
                </person-group>
                <article-title>Multiple lentigines syndrome. Case report and review of the literature.</article-title>
                <source>Am J Med.</source>
                <year>1976</year>
                <month>Mar</month>
                <volume>60</volume>
                <issue>3</issue>
                <fpage>447</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">1258892</pub-id>
              </element-citation>
            </ref>
            <ref id="leopard.REF.witt.1986.150">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Witt</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keena</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allanson</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>1986</year>
                <article-title>Growth curves for height in Noonan syndrome.</article-title>
                <source>Clin Genet</source>
                <volume>30</volume>
                <fpage>150</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">3780030</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="leopard.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="leopard.Acknowledgments">
          <title>Acknowledgments</title>
          <p>This work was supported in part by grants from: the National Institutes of Health (HL071207) to BDG; and Telethon-Italy (GGP13107), Associazione Italiana Ricerca sul Cancro (AIRC, IG13360) and Ministry of Health (RF-2011-02349938) to MT.</p>
        </sec>
        <sec id="leopard.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>14 May 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>16 November 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>30 November 2007 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>13 November 2007 (bdg) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
